Drug or treatment

Ibrutinib clinical trials

• 22Clinical trials
• 36Countries

Newest trials

All recruiting trials (22)

• Ibrutinib and Venetoclax in CLL/SLL: Long-Term Outcomes After Frontline CAPTIVATE

  This study follows people with CLL or SLL who previously received the ibrutinib plus venetoclax combination in CAPTIVATE to see how they do over time and what treatments they need if the disease returns.

  Recruiting European Research Initiative on CLL · Milan · NCT07774390

• Ibrutinib and Venetoclax for Chronic Lymphocytic Leukemia in Real-World Care

  This study tests whether a fixed-duration Ibrutinib plus Venetoclax treatment works in real-world care for people with CLL or SLL.

  Recruiting Janssen Research & Development, LLC · Bucharest · NCT07602088

• Epcoritamab plus ibrutinib for central nervous system lymphoma

  This trial tests whether combining epcoritamab and ibrutinib is safe and tolerable for adults with relapsed or refractory primary or secondary central nervous system lymphoma.

  Recruiting at 8 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07082868

• Using acalabrutinib to treat chronic lymphocytic leukemia and small lymphocytic lymphoma

  This study is testing if acalabrutinib can safely treat people with chronic lymphocytic leukemia or small lymphocytic lymphoma who can't tolerate ibrutinib, while also keeping an eye on their heart health.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06757647

• ViPOR combination therapy for relapsed or refractory aggressive B‑cell lymphoma

  This treatment will try a five‑drug targeted combination called ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in adults whose aggressive B‑cell lymphoma has relapsed or not responded to prior therapy, focusing on specific genetic subtypes like CD10‑negative DLBCL and high‑grade B‑cell lympho

  Recruiting at 99 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 114 other locations · NCT06649812

• Combination treatment of epcoritamab and ibrutinib for aggressive B-cell lymphoma

  This study is testing a new combination of two treatments, epcoritamab and ibrutinib, to see if they can help people with aggressive B-cell lymphoma that hasn't responded to other therapies.

  Recruiting at 3 sites Phase 1/2 Ohio State University Comprehensive Cancer Center · Minneapolis, Minnesota and 2 other locations · NCT06536049

• CAR-T-cell treatment for high-risk mantle cell lymphoma

  This study is testing a new CAR-T-cell treatment for high-risk mantle cell lymphoma to see if it works better than standard therapies for younger and healthier elderly patients.

  Recruiting at 2 sites Phase 2 Ludwig-Maximilians - University of Munich · Mainz and 1 other locations · NCT06482684

• Glofitamab plus ibrutinib and obinutuzumab for mantle cell lymphoma

  This trial will see if combining glofitamab with ibrutinib and obinutuzumab is safe and effective for adults with previously untreated, high‑risk or age‑65‑and‑older mantle cell lymphoma.

  Recruiting Phase 1/2 OHSU Knight Cancer Institute · Portland, Oregon · NCT06357676

• Impact of physical activity on quality of life for patients with chronic lymphocytic leukemia

  This study is testing if adding physical activity to the routine of patients with chronic lymphocytic leukemia starting ibrutinib treatment can improve their quality of life.

  Recruiting Janssen Cilag S.A.S. · Toulouse · NCT06299540

• Comparing Nemtabrutinib to Ibrutinib or Acalabrutinib for First Line Treatment of Chronic Lymphocytic Leukemia

  This study is testing if a new drug called nemtabrutinib works as well as or better than two existing treatments for people with chronic lymphocytic leukemia who haven’t had treatment before.

  Recruiting at 181 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 205 other locations · NCT06136559

• Combining Ibrutinib with standard treatment for patients with primary CNS lymphoma who can't undergo transplant

  This study is testing if combining the drug ibrutinib with standard treatments can help patients with primary CNS lymphoma who can't have a transplant live better and longer.

  Recruiting at 8 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 7 other locations · NCT05998642

• Using ibrutinib to treat autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia

  This study is testing if the drug ibrutinib can help adults with chronic lymphocytic leukemia who also have autoimmune hemolytic anemia feel better.

  Recruiting at 3 sites Phase 2 Gruppo Italiano Malattie EMatologiche dell'Adulto · Florence and 2 other locations · NCT05694312

• Pirtobrutinib versus ibrutinib for people with CLL or SLL.

  This trial will test whether pirtobrutinib works better or is safer than ibrutinib for adults with CLL/SLL, with a separate part that tries pirtobrutinib alone in treatment‑naïve patients who have a 17p deletion.

  Recruiting at 93 sites Phase 3 Eli Lilly and Company · Anaheim, California and 142 other locations · NCT05254743

• Combining Ibrutinib and Indoximod for Pediatric Brain Cancer Treatment

  This study is testing a new combination of two drugs, ibrutinib and indoximod, to see if they can safely help children and young adults with hard-to-treat brain tumors feel better.

  Recruiting Phase 1 Augusta University · Augusta, Georgia · NCT05106296

• Fixed-duration treatment for chronic lymphocytic leukemia with ibrutinib and obinutuzumab

  This study is testing a new treatment plan using ibrutinib and obinutuzumab for people with chronic lymphocytic leukemia who haven't been treated before, to see if it can help them reach a point where the disease is undetectable in their bone marrow.

  Recruiting Phase 2 IRCCS San Raffaele · Milan, MI · NCT04908228

• Comparing venetoclax and rituximab to ibrutinib and rituximab for treating Waldenstrom's macroglobulinemia

  This study is testing whether a new combination of venetoclax and rituximab works better than the standard treatment of ibrutinib and rituximab for people with Waldenstrom's macroglobulinemia who haven't been treated before.

  Recruiting at 106 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 149 other locations · NCT04840602

• Intermittent dosing of ibrutinib for advanced chronic lymphocytic leukemia

  This study is testing if taking the cancer drug ibrutinib in a 'ON-OFF' way can help people with advanced chronic lymphocytic leukemia stay healthy while possibly having fewer side effects and lower costs.

  Recruiting at 6 sites Phase 1/2 Karolinska University Hospital · Trondheim and 8 other locations · NCT04771507

• Combining Venetoclax, Rituximab, and Ibrutinib for Treating Chronic Lymphocytic Leukemia

  This study is testing if adding ibrutinib to a year-long treatment of venetoclax and rituximab can help people with newly diagnosed Chronic Lymphocytic Leukemia reach a state where the disease is undetectable.

  Recruiting Phase 2 IRCCS San Raffaele · Milan, MI · NCT04758975

• Combination therapy for recurrent primary central nervous system lymphoma

  This study is testing a new combination of three medications to see if it can help people with recurrent primary central nervous system lymphoma feel better after their previous treatments didn't work.

  Recruiting at 3 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 3 other locations · NCT04421560

• Comparing two treatment approaches for Waldenström's macroglobulinaemia

  This study is testing a new treatment without chemotherapy for people with Waldenström's macroglobulinaemia to see if it works better and is easier on the body than the standard treatment.

  Recruiting at 25 sites Phase 2/3 University College, London · Bath and 24 other locations · NCT04061512

• Evaluating a new treatment approach for chronic lymphocytic leukemia

  This study is testing a new treatment plan that combines two established therapies with ibrutinib to see if it helps people with chronic lymphocytic leukemia who haven't had treatment before.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT03980002

• Combination treatment for relapsed B-cell lymphoma

  This study is testing a new combination of five drugs to see if it can help people with relapsed or hard-to-treat B-cell lymphoma feel better.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03223610

Quick answers

How many clinical trials of Ibrutinib are recruiting right now?

22, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 36 countries. The most sites are in United States (11 trials), Italy (5 trials), Canada (3 trials), China (3 trials), Germany (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 9, Phase 1/2: 5, Phase 1: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →